By Fineline Cube Shanghai-based Kangpu Biopharmaceuticals, Ltd has announced the first patient dosing in a multicenter, randomized, double-blind, placebo-controlled Phase IIa clinical study. The trial aims to evaluate the safety, tolerability, pharmacokinetics, and preliminary efficacy of KPG-818, an orally bioavailable NeoMIDES molecular glue, in patients with systemic lupus erythematosus (SLE).
Mechanism and Development
KPG-818 is a novel orally bioavailable modulator of the E3 ubiquitin ligase complex containing cereblon (CRL4-CRBN E3 ubiquitin ligase). It is being developed for the treatment of autoimmune diseases and hematologic malignancies. In a recent Phase Ib clinical study in the US, KPG-818 showed good tolerability, favorable pharmacokinetics, and significant potency for degrading Ikaros and Aiolos (IKZF1 and IKZF3).
Company Overview
Kangpu is a clinical-stage company focused on discovering and developing innovative small molecules for solid tumors, hematologic malignancies, autoimmune diseases, and inflammatory disorders. The company employs novel solutions such as targeted protein ubiquitination and degradation. Kangpu has built a robust pipeline of potential first-in-class and best-in-class drug candidates based on its proprietary technology platforms, including NeoMIDES, SelPDEiS, and X-SYNERGY, all patented worldwide.-Fineline Info & Tech